Supplying a pharmacy for NASA exploration spaceflight: challenges and current understanding.
| Autor: | Blue RS; 1Aerospace Medicine and Vestibular Research Laboratory, The Mayo Clinic Arizona, Scottsdale, AZ 85054 USA.; 2GeoControl Systems, Inc, Houston, TX 77058 USA., Bayuse TM; 3KBR, Houston, TX 77058 USA., Daniels VR; 3KBR, Houston, TX 77058 USA., Wotring VE; 4Department of Pharmacology and Chemical Biology and Center for Space Medicine, Baylor College of Medicine, Houston, TX 77030 USA., Suresh R; 5Department of Preventive Medicine and Community Health, University of Texas Medical Branch, Galveston, TX 77555-1110 USA., Mulcahy RA; 6National Aeronautics and Space Administration (NASA), Johnson Space Center, Houston, TX 77058 USA., Antonsen EL; 6National Aeronautics and Space Administration (NASA), Johnson Space Center, Houston, TX 77058 USA.; 7Department of Emergency Medicine and Center for Space Medicine, Baylor College of Medicine, Houston, TX 77030 USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | NPJ microgravity [NPJ Microgravity] 2019 Jun 13; Vol. 5, pp. 14. Date of Electronic Publication: 2019 Jun 13 (Print Publication: 2019). |
| DOI: | 10.1038/s41526-019-0075-2 |
| Abstrakt: | In order to maintain crew health and performance during long-duration spaceflight outside of low-Earth orbit, NASA and its international partners must be capable of providing a safe and effective pharmacy. Given few directed studies of pharmaceuticals in the space environment, it is difficult to characterize pharmaceutical effectiveness or stability during spaceflight; this in turn makes it challenging to select an appropriate formulary for exploration. Here, we present the current state of literature regarding pharmaceutical stability, metabolism, and effectiveness during spaceflight. In particular, we have attempted to highlight the gaps in current knowledge and the difficulties in translating terrestrial-based drug studies to a meaningful interpretation of drug stability, safety, and effectiveness in space. We hope to identify high-yield opportunities for future research that might better define and mitigate pharmaceutical risk for exploration missions. Competing Interests: Competing interestsThe authors declare no competing interests. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|